Form 4 for BDTX Black Diamond Therapeutics, Inc.
Accepted 2023-02-15 00:00:00 ET · period of report 2023-02-13 · accession 0001104659-23-022388 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-15 | 2023-02-13 | BDTX | Jones Erika | SEE REMARKS | A - Grant | $0.00 | +5,075 | 10.2K | +100% | $0 |
| D | 2023-02-15 | 2023-02-13 | BDTX | Jones Erika | SEE REMARKS | A - Grant | $0.00 | +60.0K | 60.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-13 | A | A | 5,075 | $0.00 | 10,150 | D | — | — | (F1) The Reporting Person was previously granted performance-based Restricted Stock Units ("RSUs"). The vesting of 35% of the RSUs was subject to the achievement of certain performance criteria. As of the transaction date, the performance criteria were met, resulting in the vesting of 1,776 RSUs, with the remainder vesting on August 15, 2023, subject to the grantee's continuous service through such vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-02-13 | A | A | 60,000 | $0.00 | 60,000 | D | $2.92 · — to 2033-02-12 | 60,000 Common Stock | (F2) 25% of the shares subject to this option shall vest and become exercisable on February 13, 2024, with the remainder vesting in 36 equal monthly installments thereafter. |